Table 4.
Demographics and baseline characteristics of patients with a best response of CR per the investigator by current status
| CR and in remission* (n = 16) | All other CR† (n = 18) | |
|---|---|---|
| Median age in years (range) | 26.5 (15-63) | 38.5 (21-51) |
| Female, n (%) | 10 (63) | 13 (72) |
| ECOG performance status, n (%) | ||
| Grade 0 | 9 (56) | 9 (50) |
| Grade 1 | 7 (44) | 9 (50) |
| Relapsed relative to most recent therapy,‡ n (%) | 12 (75) | 11 (61) |
| Primary refractory disease,§ n (%) | 12 (75) | 12 (67) |
| Stage, n (%) | ||
| Stage I/II | 12 (75) | 12 (67) |
| Stage III | 3 (19) | 2 (11) |
| Stage IV | 1 (6) | 3 (17) |
| Median time in months from initial diagnosis to first dose (range) | 36.5 (16-99) | 45.8 (14-185) |
| Median time in months from last auto-SCT to relapse prior to b-v (range) | 8.4 (1-63) | 8.9 (2-31) |
| Median SPD (cm2) per investigator (range) | 16.1 (2-55) | 17.3 (3-116) |
b-v, brentuximab vedotin.
*
Patients with a best response of CR on treatment who are still on study and in remission without the start of new anticancer therapy, other than allogeneic stem cell transplant.
†
Patients with a best response of CR on treatment who either: experienced progressive disease, initiated new therapy, or discontinued from the study for reasons including death, lost to follow-up, withdrawal of consent, and investigator decision.
‡
Best response of CR or PR to most recent prior therapy.
§
No CR or relapse within 3 months of front-line therapy.